Search results for "dental management"
showing 3 items of 3 documents
Management of children with autism spectrum disorder in the dental setting
2013
Objectives: This article reviews the present literature on the issues encountered while coping with children with autistic spectrum disorder from the dental perspective. The autistic patient profile and external factors affecting the oral health status of this patient population are discussed upon the existing body of evidence. Material and Methods: The MEDLINE database was searched using the terms ‘Autistic Disorder’, ‘Behaviour Control/methods’, ‘Child’, ‘Dental care for disabled’, ‘Education’, ‘Oral Health’, and ‘Pediatric Dentistry’ to locate related articles published up to January 2013. Results: Most of the relevant studies indicate poor oral hygiene whereas they are inconclusive rega…
Strategie preventive e management odontoiatrico nel paziente a rischio di osteonecrosi delle ossa mascellari associata a farmaco
2017
Osteonecrosis of the jaw (ONJ) drug related is an uncommon but serious and debilitating disease, whose epidemiology and pathogenesis are still unclear. However, in the recent years, knowledge regarding ONJ risk factors has lead to substantial progress in ONJ prevention. Anti-resorptive medicines (e.g. bisphosphonates, denosumab) and anti-angiogenic medicines (e.g bevacizumab, sunitinib) are being used in the treatment of various cancers and in the treatment of several non-oncological conditions, mainly for the osteoporosis. Despite the higher frequencies of ONJ cases in cancer patients, ONJ is becoming more frequent in everyday practice in osteometabolic patients. This due to the higher num…
Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab
2020
Denosumab (DNB) is a bone-targeted medication used to preserve structural integrity and minimise the risk of fragility fractures in metastatic cancer and metabolic bone disorders. DNB targets and binds RANK Ligand, inhibiting osteoclast maturation, function, and survival. In contrast with nitrogen-containing bisphosphonates (N-BPs), DNB does not bind to hydroxyapatite and incorporate into bone; thus, bone cellular remodelling recovers rapidly after drug suspension. Denosumab has benn linked to the occurrence of osteonecrosis of the jaw (MRONJ), a uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Althou…